1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,950 | 7,100 | 16.12. | |
| 6,850 | 7,050 | 16.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.11. | Elicio Therapeutics appoints Marc Wolfgang as chief technology officer | 1 | Investing.com | ||
| 19.11. | Elicio Therapeutics Inc.: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer | 355 | GlobeNewswire (Europe) | BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 13.11. | Elicio Therapeutics GAAP EPS of -$0.60 misses by $0.12 | 2 | Seeking Alpha | ||
| 13.11. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | 152 | GlobeNewswire (Europe) | In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC"), fewer disease progressions and deaths than projected have been observed as... ► Artikel lesen | |
| 07.11. | Elicio meldet starke Immunantworten in Phase-2-Studie zu KRAS-Krebsimpfstoff | 1 | Investing.com Deutsch | ||
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.11. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC | 170 | GlobeNewswire (Europe) | SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002... ► Artikel lesen | |
| 27.10. | Krebstherapie von Elicio zeigt breite Immunantwort bei diversen HLA-Typen | 1 | Investing.com Deutsch | ||
| 27.10. | Elicio's cancer therapy shows immune response across diverse HLA types | 1 | Investing.com | ||
| 18.09. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 179 | GlobeNewswire (Europe) | BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| 17.09. | Elicio Reports Strong T Cell Responses In Phase 2 Trial Of Cancer Vaccine | 1 | RTTNews | ||
| 17.09. | Elicio: Krebsimpfstoff ELI-002 löst bei 99 % der Patienten starke Immunantwort aus | 2 | Investing.com Deutsch | ||
| 17.09. | Elicio's cancer vaccine ELI-002 shows strong immune response in 99% of patients | 2 | Investing.com | ||
| 17.09. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial | 166 | GlobeNewswire (Europe) | ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapyRobust mKRAS-specific T cell responses were observed... ► Artikel lesen | |
| 12.08. | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease ("MRD") Positive, Adjuvant-Stage Patients | 203 | GlobeNewswire (Europe) | At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS... ► Artikel lesen | |
| 12.08. | Elicio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.08. | Elicio Therapeutics GAAP EPS of -$0.66 | 2 | Seeking Alpha | ||
| 07.08. | Elicio Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | 306 | GlobeNewswire (Europe) | Recent positive recommendation by the Independent Data Monitoring Committee ("IDMC") to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven... ► Artikel lesen | |
| 05.08. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,480 | -2,95 % | EQS-News: NanoRepro AG: Aufsichtsratsmitglied kündigt Amtsniederlegung an | EQS-News: NanoRepro AG
/ Schlagwort(e): Personalie
NanoRepro AG: Aufsichtsratsmitglied kündigt Amtsniederlegung an
10.12.2025 / 08:35 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| OCUGEN | 1,283 | +2,15 % | Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit | ||
| VIKING THERAPEUTICS | 30,460 | +0,21 % | 1 Bold Prediction for Viking Therapeutics in 2026 | ||
| COSCIENS BIOPHARMA | 1,760 | 0,00 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| BIOCRYST PHARMACEUTICALS | 6,400 | +0,44 % | XFRA BO1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCRYST PHARMAC.... ► Artikel lesen | |
| VAXART | 0,281 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| IBIO | 1,490 | -15,82 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,205 | +1,26 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,920 | +0,41 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| CARDIFF ONCOLOGY | 2,030 | -0,73 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| MANNKIND | 5,020 | -0,12 % | MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease | If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially provide a cost-effective and convenient... ► Artikel lesen | |
| ALDEYRA | 4,465 | -1,13 % | Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says | ||
| TRAWS PHARMA | 2,220 | -0,89 % | Traws Pharma, Inc. - 8-K, Current Report | ||
| COHERUS ONCOLOGY | 1,173 | -0,55 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen |
ELICIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,150 (+2,16 %) liegt der Kurs bei 7,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.